Giuseppe Giaccone
机构: Professor of Medicine, Weill Cornell University
每年引用次数
引用次数
引用: 85,795
H-指数: 143
I10-指数 : 624
出版物: 1,224
A phase I dose escalation study with anti-CD44V6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus
R. De Bree , B.M. Tijink , J. Buter , G. Giaccone
Radiotherapy and Oncology 82
2007
Comparison of enzastaurin pharmacokinetics and safety in the once daily (QD) and twice daily (BID) dose regimens: A phase I study
A. Hanauske , L. Musib , K. Weigang-Köhler , E. Yilmaz
Journal of Clinical Oncology 25 14021 -14021
1
2007
A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full-dose cetuximab in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy
C. R. Garrett , L. L. Siu , G. Giaccone , A. El-Khoueiry
Journal of Clinical Oncology 25 14018 -14018
4
2007
The determination of gemcitabine and 2′-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry
R. Honeywell , A.C. Laan , C.J. van Groeningen , E. Strocchi
Journal of Chromatography B 847 ( 2) 142 -152
43
2007
Cancer of the esophagus and gastric cardia: recent advances*
G. N. J. Tytgat , H. Bartelink , R. Bernards , G. Giaccone
Diseases of The Esophagus 17 ( 1) 10 -26
68
2004
Pharmacokinetics (PK) and pharmacodynamics (PD) of SDZ PSC 833, a novel multidrug resistance reversing agent, in phase 1 trials with chemotherapeutic agents
S.B. Charnick , P. Fracasso , M. Egorin , P. Sonneveld
European Journal of Cancer 33
1
1997
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.
M. Smoragiewicz , J. Bogaerts , E. Calvo , A. Marabelle
Annals of Oncology 29 ( 11) 2175 -2182
10
2018
A phase I study of paclitaxel, carboplatin, and YM155 (survivin suppressor) in subjects with solid tumors.
R. J. Kelly , A. Rajan , G. Chun , A. Lopez-Chavez
Journal of Clinical Oncology 29 3090 -3090
3
2011
Array-based comparative genomic hybridization analysis to identify prognostic markers for resected pancreatic cancer.
J. Lee , I. Petrini , J. Hwang , E. Giovannetti
Journal of Clinical Oncology 29 ( 15_suppl) 4097 -4097
2011
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
B Coudert , T Ciuleanu , K Park , Y-L Wu
Annals of Oncology 23 ( 2) 388 -394
136
2012
A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer
A.W. Tolcher , D.I. Quinn , A. Ferrari , F. Ahmann
Annals of Oncology 23 ( 4) 968 -973
106
2012
Src as a potential therapeutic target in non-small-cell lung cancer
G. Giaccone , P.A. Zucali
Annals of Oncology 19 ( 7) 1219 -1223
68
2008
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
P.A. Zucali , M.G. Ruiz , E. Giovannetti , A. Destro
Annals of Oncology 19 ( 9) 1605 -1612
82
2008
Newer opportunities in systemic therapy of lung cancer
A. Rajan , M. Gutierrez , G. Giaccone
Annals of Oncology 19
6
2008
Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer
A.-R. Hanauske , M. Lahn , L.C. Musib , K. Weigang-Köhler
Annals of Oncology 20 ( 9) 1565 -1575
20
2009
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors
J.-C. Soria , F.A. Shepherd , J.-Y. Douillard , J. Wolf
Annals of Oncology 20 ( 10) 1674 -1681
153
2009
Phase I trial of SU14813 in patients with advanced solid malignancies
W. Fiedler , G. Giaccone , P. Lasch , I. van der Horst
Annals of Oncology 22 ( 1) 195 -201
24
2011
A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.
G. Giaccone , L.A. Bazhenova , J. Nemunaitis , M. Tan
European Journal of Cancer 51 ( 16) 2321 -2329
122
2015
Why has active immunotherapy not worked in lung cancer
A. Thomas , G. Giaccone
Annals of Oncology 26 ( 11) 2213 -2220
29
2015
355TiPPhase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1–selected chemotherapy-naïve patients with advanced NSCLC
R.S. Herbst , F. de Marinis , J. Jassem , D.R. Spigel
Annals of Oncology 26
4
2015